Back to Search
MICHAEL CARDUCCI, M.D.
M.D.
Medical Oncology Physician
NPI: 1952369977Individual
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
D42979(MD)
Education
WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE
Class of 1988
Research & Publications (20)
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.
PMID 17886253·Cancer·2007
3-trial
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
PMID 16943527·J Clin Oncol·2006
3-trial
Targeting bone metastasis in prostate cancer with endothelin receptor antagonists.
PMID 17062717·Clin Cancer Res·2006
6-review
Multidisciplinary management of advanced prostate cancer: changing perspectives on referring patients and enhancing collaboration between oncologists and urologists in clinical trials.
PMID 15885275·Urology·2005
8-other
Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial.
PMID 12586806·J Clin Oncol·2003
3-trial
Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics.
PMID 11956279·J Clin Oncol·2002
3-trial
A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule.
PMID 11595694·Clin Cancer Res·2001
3-trial
Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo.
PMID 19372553·Mol Cancer Ther·2009
7-preclinical
Concordance of cancer patients' function, symptoms, and supportive care needs.
PMID 19657724·Qual Life Res·2009
8-other
NCCN clinical practice guidelines in oncology: testicular cancer.
PMID 19555582·J Natl Compr Canc Netw·2009
6-review
NCCN clinical practice guidelines in oncology: kidney cancer.
PMID 19555584·J Natl Compr Canc Netw·2009
6-review
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer.
PMID 19363497·Nat Med·2009
7-preclinical
HIF-1alpha inhibition as a novel mechanism of cardiac glycosides in cancer therapeutics.
PMID 19236270·Expert Opin Investig Drugs·2009
8-other
Fenugreek: a naturally occurring edible spice as an anticancer agent.
PMID 19197146·Cancer Biol Ther·2009
8-other
Pharmacogenetic pathway analysis of docetaxel elimination.
PMID 18509327·Clin Pharmacol Ther·2009
4-observational
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research.
PMID 19213669·Clin Genitourin Cancer·2009
8-other
Topical tacrolimus treatment for localized pretibial bullous phemphigoid.
PMID 18410329·J Eur Acad Dermatol Venereol·2009
5-case
A multiple-loop, double-cube microarray design applied to prostate cancer cell lines with variable sensitivity to histone deacetylase inhibitors.
PMID 18980983·Clin Cancer Res·2008
8-other
Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer.
PMID 18785254·Cancer·2008
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 600 N WOLFE ST
BALTIMORE, MD 21287 - Phone
- (410) 955-8964
Quick Facts
- NPI
- 1952369977
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 38
- Publications
- 20
Are you this provider?
Claim Your Profile